Fatigue dimension scores and medication use
| Subjects | Reduced Activity | Reduced Motivation | General Fatigue | Physical Fatigue | Mental Fatigue | Total | |
| PGI2 | 8 | 11.42±3.98 (4–20) | 11.00*±3.67 (4–20) | 14.00±3.71 (5–20) | 13.65±3.57 (4–20) | 11.03±4.33 (4–20) | 61.10±14.54 (28–91) |
| PDEI | 15 | 11.51±4.02 (4–20) | 10.63±3.64 (4–20) | 13.77±3.39 (5–20) | 13.43±3.51 (4–20) | 10.57±4.03 (4–20) | 59.90±14.51 (27–92) |
| ERA | 9 | 11.42±4.17 (4–19) | 10.31±4.00 (4–20) | 13.73±3.66 (5–20) | 12.88±4.00 (5–20) | 10.17±4.14 (4–19) | 58.52±15.98 (26–87) |
| PGI2+PDEI | 25 | 11.79±3.97 (4–20) | 11.32*±3.62 (4–20) | 14.49**±3.59 (5–20) | 13.81±3.57 (4–20) | 11.28±4.48 (4–20) | 62.68*±14.24 (28–91) |
| PGI2+ERA | 7 | 12.19±3.50 (4–19) | 11.50±3.87 (4–20) | 14.92*±3.48 (5–20) | 13.46±3.73 (5–20) | 11.85±4.54 (4–19) | 63.92*±13.67 (33–87) |
| PDEI+ERA | 20 | 11.03±3.96 (4–19) | 10.42±4.15 (4–20) | 13.92±3.46 (5–20) | 12.81±3.64 (6–20) | 10.53±4.40 (4–19) | 58.69±15.55 (27–87) |
| PGI2+PDEI+ERA | 23 | 12.71±3.33 (5–19) | 11.90*±4.06 (4–20) | 15.57**±3.20 (5–20) | 14.00±3.52 (7–20) | 12.05*±4.60 (4–19) | 66.24*±12.78 (34–87) |
Data are presented as n or mean±sd (minimum–maximum). PGI2: prostaglandin I2; PDEI: phosphodiesterase inhibitor; ERA: endothelin receptor antagonist. Only “Yes” descriptive statistics are reported. *: p<0.05; **: p<0.01. Asterisks follow the higher mean for the fatigue dimension.